. The preventive effects of edaravone on cardiomyocytes 2 apoptosis, necrosis, as well as myocardial injury following ischemia reperfusion are 3 well documented (Kikuchi et al. 2012; Kikuchi et al. 2011; Tsujita et al. 2004) . In 4 clinical studies, a reduction in antioxidant activity in heart occurs early after the 5 diagnosis of type 1 diabetes mellitus, which may result in the development of diabetic 6 cardiovascular complications (Marra et al. 2002) . As an anti-oxidant regent, whether 7 edaravone protects heart function during the development of diabetes is unknown.
8
The mechanism of edaravone's ROS scavenger effects is still unclear. In the process 9 of ROS elimination, an intracellular regulatory protein Sirtuin-1 (SIRT-1) responds to 10 insulin sensitivity plays an important role in regulating anti-oxidant activity in 11 mitochondrial, SIRT-1 can bind to peroxisome proliferator activated receptor G 12 coactivator 1α (PGC-1α), which then can be deacetylated and activated. Activated Type 1 diabetic model was induced with a single intraperitoneal injection of 4 streptozocin (STZ) (60 mg/kg) in our rats as described previously (Vallejo et al. 2014) .
5
STZ was freshly dissolved in citrate buffer (0.1 M). Control animals received the 6 buffer only. 7 days after the injection a drop of blood was collected from the tail vein 7 and blood glucose concentration was determined by using a digital blood glucose 8 meter (Accu-Chek® Sensor, Roche, Mannheim, Germany). Animals with a random 9 blood glucose level >16.7 mmol/L were considered to be diabetic and were included 10 into the study. Rats were divided randomly into three groups: vehicle-treated control 11 (CON; n = 12), vehicle treated diabetic (Model; n = 12) and edaravone-treated 12 diabetic (EDA; n = 10) groups. Animals were treated with saline or with edaravone (6 13 mg/kg/day) by intraperitoneal injection for 4 weeks.
Transthoracic two-dimensional M-mode echocardiogram pulsed wave Doppler 2 spectral tracings were obtained from CON, Model and EDA animals using a 3 Sequioa-512 Ultrasound System (Siemens AG, Munich, Germany) with a 15-MHz 4 transducer in rats anesthetized using 0.3% Pentobarbital sodium (intraperitoneal 5 injection) according to previously described (Chang et al. 2015) . M-mode tracings 6 were used to measure LV end-diastolic diameter (LVDD), percent ejection fraction 7 (EF%) and interventricular septal thickness (IVS). Doppler flow velocities across the 8 mitral valves were determined by measurement of early ventricular filling peak 9 velocity (E wave) and late filling velocity (A wave) during the systolic and diastolic 10 phase. E wave to A wave ratio (E/A) were used to determine diastolic function. Type 1 diabetic rats were killed after 4 weeks with or without EDA treatment.
6
No difference in body weight was observed between Model and EDA rats (Table 1) . PGC-1α, NRF-2 and Bcl-2 and reduces Bax and Caspase-3 (Fig.4A , B, C). significantly increased the expression of SIRT-1, PGC-1α and NRF-2 (Fig.6A, B, C) . Bcl-2. In addition, knockdown SIRT-1 resulted in a decreased NRF-2, hence 5 increased apoptotic protein expression. These data suggest that anti-apoptotic effect of 6 edaravone in the diabetic heart may be regulated, in part, through its anti-oxidant 7 action.
8
In summary, our findings demonstrate that edaravone treatment improves cardiac 9 dysfunction in diabetic rats and reduces oxidative stress and apoptosis in high Umbarkar, P., Singh, S., Arkat, S., Bodhankar, S. L., Lohidasan, S., and Sitasawad, S. Yamazaki, K., Miwa, S., Toyokuni, S., Nemoto, S., Oriyanhan, W., Takaba, K., et al. Expression of SIRT-1 (A), PGC-1α (B) and NRF-2 (C) were determined in Control, Knockdown SIRT-1siRNA were performed as described in Materials and Methods, 
